Clinical Trial Update: Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30 and 50 in adults with Type 2 diabetes; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoMix 30 (insulin aspart protamine fixed-dose combination)
• NovoMix 50 (biphasic insulin aspart 50)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED